BAROnova has submitted a premarket approval application to FDA for an implantable device designed to treat obesity.
The FDA-cleared system customizes implants as well as surgical instruments to get the best fit for each patient.
The Austin, TX-based company has been awarded a grant for nearly $3 million from the Department of Defense to develop its drug-delivery device.
The EndoBarrier has faced numerous issues over the past few years and has even had its CE mark taken away and its first pivotal study in the U.S. halted.
Boston Scientific is buying Veniti, a firm that has developed a stent system for treating venous obstructive disease, in a deal worth up to $160 million.
FDA extended the indication for Cianna Medical's Scout reflector, allowing the device to be used to mark soft tissue sites including lymph nodes.
Some of medtech’s largest companies are working for approval in the TMVR space, which could one day rival or surpass TAVR.
The two technology groups will collaborate to expand SCHOTT’s hermetic packaging portfolio with an innovative new glass micro bonding technology that will create new possibilities for electronic implantable devices.
Abbott acquired Tendyne back in 2015, a year where there was significant M&A activity in the transcatheter mitral valve replacement space.
With more investments and potential device clearances on the way, the Bioelectronics market is beginning to take off.
The Natick, MA-based company has just completed enrollment in the ENLIGHTEN clinical trial and could have topline results from the study available in 2019.
Bayer plans to discontinue sales of the Essure birth control implant in the United States, citing a decline in U.S. sales of the device.
Cleveland Clinic physicians have completed a study that shows leadless pacemakers might be a safer option than traditional transvenous pacemakers.